

Amendments to claims:


This listing of claims will replace all prior versions and listings of claims in the application.

Please amend claims 1, 3 to 14 and 16 as indicated.

Please cancel claims 2, 15 and 19 without prejudice or disclaimer.

Please add new claims 20 to 31.

Claim 1 (currently amended): A pharmaceutically acceptable sulfonic acid addition salt in crystalline form of a compound of formula I,



wherein

R¹ is C₁₋₂ alkyl substituted with one or more fluoro substituents;

R² is C₁₋₂ alkyl; and

n is 0, 1, or 2.

Claim 2 (cancelled).

Claim 3 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1, wherein the sulfonic acid is methanesulfonic acid, n-propanesulfonic acid, benzenesulfonic acid, 1,5-naphthalenedisulfonic acid, or n-butanesulfonic acid.

Claim 4 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1, wherein R¹ is -CHF₂-OCHF₂- or -CH₂CH₂F-OCH₂CH₂F.

Claim 5 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1, wherein R² is methyl.

Claim 6 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1, wherein n is 0 or 2.

Claim 7 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1, wherein the compound of formula I is Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe).

Claim 8 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1 in substantially crystalline form.

Claim 9 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1 in partially crystalline form.

Claim 10 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1 8, wherein n is 0.

Claim 11 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1 9, wherein n is 2.

Claim 12 (currently amended): The sulfonic An-acid addition salt as claimed in claim 1 10, which is Ph(3-Cl)(5-OCHF₂)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) benzenesulfonic ~~benzene-~~ sulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d values at 5.9, 4.73, 4.09, and 4.08 Å.

Claim 13 (currently amended): The sulfonic an-acid addition salt as claimed in claim 1 ~~11~~, which is $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab}(2,6\text{-diF})(\text{OMe})$ hemi-1,5-naphthalenedisulfonic acid salt, ~~characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69, and 3.63 Å.~~

Claim 14 (currently amended): A process for the preparation of a sulfonic an-acid addition salt as claimed in any one of claims 1, 3, 7, 12 and 13 ~~to 3~~, which process comprises addition of the sulfonic an-acid to a compound of formula I.

Claim 15 (cancelled).

Claim 16 (currently amended): A pharmaceutical formulation comprising a sulfonic an-acid addition salt of any one of claims 1, 3, 7, 12 and 13 ~~to 3~~, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

Claim 17-19 (cancelled).

Claim 20 (new): The sulfonic acid addition salt as claimed in claim 8, wherein the sulfonic acid addition salt is greater than 30% crystalline.

Claim 21 (new): The sulfonic acid addition salt as claimed in claim 8, wherein the sulfonic acid addition salt is greater than 40% crystalline.

Claim 22 (new): The sulfonic acid addition salt as claimed in claim 8, wherein the sulfonic acid addition salt is greater than 50% crystalline.

Claim 23 (new): The sulfonic acid addition salt as claimed in claim 8, wherein the sulfonic acid addition salt is greater than 60% crystalline.

Claim 24 (new): The sulfonic acid addition salt as claimed in claim 8, wherein the sulfonic acid addition salt is greater than 70% crystalline.

Claim 25 (new): The sulfonic acid addition salt as claimed in claim 8, wherein the sulfonic acid addition salt is greater than 80% crystalline.

Claim 26 (new): The sulfonic acid addition salt as claimed in claim 8, wherein the sulfonic acid addition salt is greater than 90% crystalline.

Claim 27 (new): The sulfonic acid addition salt as claimed in any one of claims 20 to 26, wherein the compound of formula I is $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab(OMe)}$ or $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe)}$.

Claim 28 (new): The sulfonic acid addition salt as claimed in claim 27, which is $\text{Ph}(3\text{-Cl})(5\text{-OCHF}_2)\text{-(R)CH(OH)C(O)-(S)Aze-Pab(OMe)}$ benzenesulfonic acid salt.

Claim 29 (new): The sulfonic acid addition salt as claimed in claim 12, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09, and 4.08 Å.

Claim 30 (new): The sulfonic acid addition salt as claimed in claim 13, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69, and 3.63 Å.

Claim 31 (new): A pharmaceutical formulation comprising a sulfonic acid addition salt of claim 12, in admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.